Medtronic’s Renal Denervation System Stumbles

The latest trial for Medtronic’s renal denervation system, a procedure used to treat drug-resistant blood pressure, was negatively impacted by the placebo effect.

Jan 27, 2014 at 10:00AM

The latest results from a study on Medtronic's (NYSE:MDT) Symplicity catheter system, announced on Jan. 9, raised a few eyebrows in the medical and investment community. The system under study performs renal denervation, a procedure that emits a radio frequency to knock out the renal sympathetic nerves, which play a role in drug-resistant high blood pressure. While earlier studies showed a small number of patients responding well to the procedure, the latest trial, SYMPLICITY HTN-3, did not meet its primary efficacy endpoint.

What did the study show?
The study used 535 patients with a starting systolic blood pressure (BP) over 160 mm Hg. While normal BP has a reading at or below 120 systolic and 80 diastolic, or 120/80 mmHg, patients with high BP have a reading greater than 140/90 mmHg. Doctors regard the reduction of high blood pressure as an effective way of reducing the risk of cardiovascular death.

The results derived from patients that underwent the procedure were regarded as no better than those of a "sham control group", or patients that did not receive treatment. Patients in the sham control group are similar to patients in other trials who receive a placebo rather than the actual drug being tested.

Patients who underwent the procedure did not experience lower blood pressure through six months. Earlier trials testing Medtronic's and other renal denervation systems did not incorporate a sham control group, so its inclusion in this study is believed to have affected the results. Data from the trial is still under review and full results should be available by the end of March.

Study results surprising to many docs
The results are a surprise based on the positive results from SYMPLICITY HTN-2, a smaller and earlier trial where blood pressure reductions at 30 months were as good as the reductions achieved in the first few months after the procedure. It's important to note that the system isn't regarded as a cure for hypertension but rather a complementary treatment to BP medication.

Some researchers believe the results from this study do not mean the end of renal denervation as a method for treating drug-resistant high blood pressure. Some smaller human trials have shown that the procedure can still be a viable way of reducing resistant hypertension. There's also a possibility that the failure is this latest trial may be related to the system under review, but it's too soon to make that determination .

Not all renal denervation systems are created equal
A different renal denervation system, the ENLIGHTN I manufactured by St. Jude Medical (NYSE:STJ), uses multiple electrodes to emit the necessary radiofrequency rather than the single-point catheter used in Medtronic's device. New data presented in October 2013 showed that 18 months after patients underwent the procedure, there was a reduction in average systolic blood pressure of 24 mm Hg. The study treated 46 patients in Australia and Europe .

St. Jude Medical's cardiovascular segment, which includes the renal denervation product, is expected to earn $350 million during fiscal 2013's fourth quarter, an increase of 4% compared to last year. The company expects fiscal 2013 fourth quarter net sales of about $1.42 billion for the period ended Dec. 28, 2013. EPS guidance was raised by $0.02 and is expected to be between $0.97 and $0.99. The market predicts that fourth quarter revenue will be $1.38 billion and EPS of $0.97, about $0.05 higher than EPS from a year ago.   . St. Jude Medical will report full year results on Jan. 22.

According to statistics quoted by Covidien (NYSE:COV), another provider of renal denervation therapies, high blood pressure is expected to grow by 30% by 2025. The company's renal denervation system, called OneShot, had favorable results in small clinical trials. However, the company announced today it would be exiting the renal denervation business, possibly due to low demand in Europe, where the device is approved for use. Covidien expects to record a $20 to $25 million after-tax charge. The news did not impact Covidien shares.

The company's latest fourth quarter numbers show their medical devices segment up 3%, earning $2.13 billion and making up the bulk of the quarter's total net sales of $2.6 billion. Net sales in this segment is expected to grow 2% to 5% in fiscal 2014, the same growth expected for overall sales. Covidien's strongest product lines are endomechanical instruments and energy, which grew 8% and 7% during the fourth quarter. For fiscal 2014, analysts are predicting revenues of approximately $10.6 billion, 3.7% higher than last year. EPS estimates range between $3.93 and $4.06.  .

My Foolish conclusion
While smaller human clinical trials show positive results on the use of renal denervation, larger and more rigorously conducted trials show the opposite. After the Jan. 9 results were reported, Medtronic shares dropped 2.4% to close at $59.36. For fiscal 2014, the company is expecting revenue growth of 3% to 4% and diluted EPS to range between $3.80 to $3.85. Analysts are predicting earnings growth of 2.5% with average revenue totaling $17 billion. Analyst EPS estimates are in line with the company's guidance.

While the Medtronic study results are still being evaluated, the jury is still out on whether renal denervation will effectively treat drug-resistant hypertension and provide Medtronic and St. Jude Medical with a return on the research conducted so far.

Top stock pick for 2014
There’s a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Eileen Rojas has no position in any stocks mentioned. The Motley Fool recommends Covidien. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers